ImmunoGen

ImmunoGen PP&E per Employee

Delisted

The PP&E per Employee of ImmunoGen (IMGN) as of Oct 20, 2026 is 260,417.72 USD. In the previous year, PP&E per Employee was 215,886.08 USD — a change of 20.63% (higher).

PP&E per Employee

260,417.72USD

YoY

20.63%

Last updated:

PP&E per Employee of ImmunoGen is 2022 260,417.72 USD. PP&E per Employee of ImmunoGen was 2021 215,886.08 USD. It decreases by 20.63% higher compared to the previous year.

The ImmunoGen PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
287,392.41 USD
Jan 1, 2016
246,810.13 USD
Jan 1, 2017
184,025.32 USD
Jan 1, 2018
163,177.22 USD
Jan 1, 2019
88,518.99 USD
Jan 1, 2020
72,911.39 USD
Jan 1, 2021
215,886.08 USD
Jan 1, 2022
260,417.72 USD
The ImmunoGen PP&E per Employee history
YEARPP&E per EmployeeYoY
260,417.72USD+20.63%
215,886.08USD+196.09%
72,911.39USD-17.63%
88,518.99USD-45.75%
163,177.22USD-11.33%
184,025.32USD-25.44%
246,810.13USD-14.12%
287,392.41USD+39.68%
205,746.84USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmunoGen Stock analysis

What does ImmunoGen do? ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmunoGen stock

PP&E per Employee of ImmunoGen is 260,417.72 USD in 2022.

PP&E per Employee of ImmunoGen changed from 215,886.08 USD to 260,417.72 USD, representing a 20.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee ImmunoGen since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's ImmunoGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ImmunoGen

All Key Metrics — ImmunoGen